Digital Health Frontier
By John Halamka and Paul Cerrato -Three patient populations are underrepresented in the AI models currently being developed. There are several practical solutions to the problem.
By John Halamka and Paul Cerrato - The history of medicine is filled with “expert” resistance to change. Marching in the brave parade of innovators who buck the system may sting, but the rewards usually outweigh the risks.
By John Halamka and Paul Cerrato - Despite some skepticism about the usefulness of AI in clinical medicine, there’s ample evidence to show CAD-assisted colonoscopy can save lives.
By John Halamka and Paul Cerrato - It’s not about fame and fortune.
By John Halamka and Paul Cerrato - AI-enabled algorithms can’t exist in an operational vacuum. To really benefit our patients, they need to be deployed with the help of an interprofessional team of experts and a set of “delivery science” principles that most developers are not aware of.
By John Halamka and Paul Cerrato - The latest proposed rules from CMS and FDA emphasize the need for a balanced, nuanced approach to digital innovation.
By John Halamka and Paul Cerrato - Challenging the status quo in technology and medicine can take a heavy toll, but history has demonstrated that it often yields measurable benefits for both clinicians and patients.
By John Halamka and Paul Cerrato - Smartphone-based applications may help detect atrial fibrillation, warn clinicians about worsening mental status, and improve the management of heart failure.
By John Halamka and Paul Cerrato - Every clinician knows that early detection is one of the most powerful tools we have in the war on cancer. Several computational tools are enabling us to make early detection a reality, at least in two specialties.
By John Halamka and Paul Cerrato - Two recent studies strongly suggest that sepsis predictive algorithms may in fact be ready for “prime time.”
By John Halamka and Paul Cerrato - A recent report points out that providers are not taking the necessary steps to secure the mobile devices connected to their network.
By John Halamka and Paul Cerrato - A growing number of studies show that drug/gene interactions can influence how patients respond to specific medications. But there are barriers that prevent the full implementation of pharmacogenomic testing into routine clinical practice.